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patients from 2000 to 2007 were matched 1:10 by age and gender to cancer-free 
controls selected from the PHARMO RLS with date of diagnosis as the index date 
for both RCC patients and their controls. TE events were deﬁned as any venous TE 
event or arterial TE event requiring hospitalization in the 12 months before or after 
index date. RESULTS: A total of 973 RCC patients were included, 6% of whom 
underwent nephrectomy. The proportion of patients with any TE event was similar 
before (2.0%, 95% CI: 1.2–3.0%) and after (1.4%, 95% CI: 0.8–2.4%) RCC diag-
nosis. Arterial TE events were more common prior to diagnosis (1.6%, 95% CI: 0.9–
2.7%) than post-diagnosis (0.5%, 95% CI: 0.2–1.2%), whereas venous TE events 
were less common prior to diagnosis (0.3%, 95% CI: 0.1–0.9%) than post-diagnosis 
(0.9%, 95% CI: 0.4–1.8%). Compared to cancer-free controls, RCC patients were 
more likely to have had a pre-diagnosis (odds ratio  2.7, 95% CI: 1.6–4.4) or post-
diagnosis (hazard ratio  2.1, 95% CI: 1.2–3.7) TE event. CONCLUSIONS: In this 
population-based study, RCC patients were twice as likely to develop TE events 
compared to cancer-free controls, although frequency of events was low. These results 
emphasize the need for careful observation of RCC patients after diagnosis.
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OBJECTIVES: TO compare efﬁcacy and safety of lenograstim and ﬁlgrastim in stem 
cell mobilization in healthy donors (allogenic transplantation) and in oncological 
patients (autologous transplantation). METHODS: Comparison was based on ran-
domized controlled trials (RCTs) identiﬁed by means of systematic review, carried out 
according to the Cochrane Collaboration guidelines. The most important medical 
databases were searched (EMBASE, MEDLINE, CENTRAL). Two reviewers indepen-
dently selected trials, assessed their quality and extracted data. Meta-analysis of 
head-to-head trials was performed to compare lenograstim and ﬁlgrastim in stem cell 
mobilization in healthy donors and oncological patients. RESULTS: The results of 4 
RCTs in healthy donors and 3 RCTs in oncological patients were included in the 
analysis. For healthy donors mobilization with lenograstim resulted in higher number 
of CD34 cells harvested than mobilization with ﬁlgrastim (WMD  0.66 r 106 per 
kg of body weight [0.05; 1.26]). No differences between lenograstim and ﬁlgrastim 
were found in the number of donors requiring second apheresis (RR  0.91 [0.62; 
1.35]). Adverse events rates were similar in both arms. Most common adverse events 
including bone pain and arthralgia. For oncological patients no differences in the 
number of patients that gained target CD34 cells (2 r 106) were found (RR  0.72 
[0.33; 1.55]). Results for hematological recovery are inconsistent. No signiﬁcant 
differences in the incidence of neutropenia were noted (RR  0.72 [0.50; 1.03]) 
whereas platelet transfusions were more frequent in ﬁlgrastim treated patients than in 
lenograstim group (RR  0.16 [0.04; 0.67]). The length of hospital stay after trans-
plantation was similar in both groups. No signiﬁcant differences regarding safety 
outcomes were reported. CONCLUSIONS: In healthy donors lenograstim is more 
potent than ﬁlgrastim in stem cell mobilization into peripheral blood and no differ-
ences in safety proﬁles between two drugs were noted. In oncological patients both 
drugs has similar impact on stem cell mobilization while lenograstim dicreases the 
risk of platelet transfusion. Acknowledgements: This analysis was supported by     
Sanoﬁ-Aventis.
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OBJECTIVES: This study compared efﬁcacy and safety of allogenic peripheral blood 
stem cell transplantation (PBSCT) after mobilization with either lenograstim or ﬁl-
grastim. METHODS: Comparison was based on randomized controlled trials (RCT) 
identiﬁed by means of systematic review, carried out according to the Cochrane Col-
laboration guidelines. The most important medical databases were searched (EMBASE, 
MEDLINE, CENTRAL). Two reviewers independently selected trials, assessed their 
quality and extracted data. Since head-to-head trials were not found, indirect com-
parison using Bucher’s method was performed. RESULTS: The results of 2 RCTs for 
PBSCT after lenograstim mobilization and 7 for PBSCT with ﬁlgrastim were included. 
In all trials PBSCT was compared with bone marrow transplantation (BMT). No sig-
niﬁcant differences between lenograstim and ﬁlgrastim were found in mortality rate 
(RR  0.84 [0.49; 1.42]) and relapse rate (RR  0.69 [0.19; 2.49]). PBSCT after 
mobilization with lenograstim comparing to BMT does not increase the risk of acute 
graft versus host disease (GvHD) (RR  1.06 [0.73; 1.53]) whereas PBSCT after ﬁl-
grastim use is associated with higher risk of acute GvHD than BMT (RR  1.19 [1.03; 
1.37]). However indirect comparison results in similar incidence of acute GvHD 
(RR  0.89 [0.60; 1.32]. The was also no difference between lenograstim and ﬁlgrastim 
in respect to chronic GvHD (RR  1.33 [0.84; 2.11]. Lenograstim and ﬁlgrastim 
in PBSCT resulted in similar mortality rate due to GvHD (RR  0.55 [0.19; 1.59]), 
treatement realted mortality (RR  1.11 [0.60; 2.04]). No differences in hospital 
admissions for donors mobilized with lenograstim and ﬁlgrastim were identiﬁed 
(RR  1.04 [0.60; 1.79]). CONCLUSIONS: Indirect comparisons indicate similar 
efﬁcacy and safety of PBSCT after mobilization with lenograstim and PBSCT after 
mobilization with ﬁlgrastim. Acknowledgements: This analysis was supported by     
Sanoﬁ-Aventis.
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OBJECTIVES: To describe the prevalence of comorbidities in the newly diagnosed 
mCRC population. METHODS: The study used a large US claims database. Patients 
aged q18 with newly diagnosed mCRC between January 2005 and June 2008 were 
selected using the ICD-9 diagnosis codes (CRC: 153.x [excluding 153.5], 154.0, 154.1, 
154.8; distant metastasis: 196.0, 196.1, 196.3, 196.5, 197.x (excluding 197.5), 198, 
199.0). The initial mCRC diagnosis date was deﬁned as the index date. One-year 
continuous medical and drug beneﬁt coverage prior to the index date was required. 
Medical diagnoses and medication treatments were examined. All comorbidities were 
estimated during 1-year except for traumatic conditions which were assessed for 30-
day prior to the index date. RESULTS: Based on the selection criteria, 12,648 patients 
were included with mean (ostandard deviation) age of 66.3 (o13.0) years, 54% male, 
and 70% with colon primary. Distribution of metastases included liver (40%), lung 
(14%), bone (6%), and brain (3%). The most prevalent comorbidity was cardiovas-
cular disease (CVD) (62% of patients) including hypertension (41%), coronary artery 
disease (17%), congestive heart failure (7%), dysrhythmias (14%), arterial thrombo-
embolism including ischemic heart disease (18.6%), and venous thromboembolism 
(6%). Over 10% of patients had a major surgery, bone fracture, or open wound 30 
days prior to mCRC diagnosis; 31% had a history of bleeding; and nearly 12% of 
patients were treated with anticoagulant and 6% with antiplatelet agents. Addition-
ally, 19% of patients had diabetes, 8% had renal failure or insufﬁciency, and 5% had 
skin disorders. Patients q65 years old had a signiﬁcantly higher CVD prevalence (73%; 
p  0.001). CONCLUSIONS: Comorbid medical conditions are common in patients 
with mCRC. CVD is the most prevalent comorbidity and affects approximately ¾ of 
patients over age 65. It is important to assess comorbidities in all patients with mCRC 
since their presence may impact treatment decision making.
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OBJECTIVES: Current options for colorectal cancer (CRC) screening include imaging 
procedures such as colonoscopy and ﬂexible sigmoidoscopy, guaiac fecal occult blood 
tests (gFOBT), and fecal immunochemical tests (FIT). Compliance with screening for 
CRC guidelines remains low among average-risk adults, at least partly because of low 
patient acceptance of available tests due to their invasiveness, inconvenience, and 
perceived safety risks. Serum tests are noninvasive, convenient, and safe, and may 
improve compliance. We systematically reviewed the literature to assess the current 
status of serum tests and other screening tests for CRC. METHODS: We analyzed 
studies of CRC screening tests identiﬁed in a search of English-language MEDLINE-
indexed articles published in the 3 years prior to March 2009 and non-MEDLINE-
indexed sources such as organization websites, meeting abstracts, and government 
publications. RESULTS: We identiﬁed 123 primary studies from MEDLINE and 45 
from non-MEDLINE sources for a total of 168 pertaining to tests or biomarkers for 
early diagnosis of CRC. Serum biomarkers being evaluated include tumor associated 
antigens, cytokines, anti-apoptotic and pro-growth factors, and hypermethylated 
DNA. Biomarkers under development have signiﬁcantly higher sensitivity for CRC 
than for adenomatous polyps, making them more effective for cancer detection than 
prevention. CRC sensitivity and speciﬁcity of certain serum biomarkers and serum 
biomarker panels under development are better than those of the existing test gFOBT 
and equivalent or better than those of FIT. However, most biomarkers in development 
are common to other cancers and diseases, reducing their speciﬁcity for CRC. CON-
CLUSIONS: Several serum biomarkers show promise in detecting CRC, but require 
testing in large, average-risk populations. Unless biomarkers are identiﬁed that are 
more speciﬁc for adenomas and/or CRC than currently known, and because of the 
heterogeneity of CRC, the approach most likely to be successful would involve the 
combination of multiple serum biomarkers to create a distinctive CRC biomarker 
proﬁle.
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OBJECTIVES: GISTs are rare tumors of the GI tract. In France, their incidence is 
estimated to be 9–12/106 inhabitants/year. Imatinib has been approved to treat 
unresectable and/or metastatic Kit-positive GISTs since 2002, but information on 
routine use, safety and efﬁcacy in unselected “real life” setting is lacking. An obser-
vational cohort (EPIGIST) in France was designed to provide data on survival, safety 
and treatment patterns and quality of life. METHODS: EPIGIST is a nationwide 
